XNAS
OCS
Market cap857mUSD
Apr 28, Last price
17.86USD
1D
5.06%
1Q
-20.02%
IPO
84.12%
Name
European Biotech Acquisition Corp
Chart & Performance
P/E
—
P/S
796.83
EPS
—
Div Yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
883k
-3.18%
Net income
-89m
L+129.47%
CFO
-47m
L-11.79%
Profile
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company's lead candidate is OCS-01, a topical dexamethasone formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for keratoconjunctivitis sicca, or dry eye disease; and OCS-05, a novel neuroprotective agent for acute optic neuritis and other neuro-ophtha disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company is based in Zug, Switzerland.
Valuation
Title CHF in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | |
| Income | |||||
Revenues | 883 -3.18% | 912 -5.00% | |||
Cost of revenue | 75,981 | 51,191 | |||
Unusual Expense (Income) | |||||
NOPBT | (75,098) | (50,279) | |||
NOPBT Margin | |||||
Operating Taxes | 107 | 55 | |||
Tax Rate | |||||
NOPAT | (75,205) | (50,334) | |||
Net income | (88,802) 129.47% | (38,698) 108.59% | |||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | 53,541 | 135,615 | 120 | ||
BB yield | -40.39% | -0.04% | |||
| Debt | |||||
Debt current | 315 | 174 | 142 | ||
Long-term debt | 2,045 | 1,036 | 123,573 | ||
Deferred revenue | |||||
Other long-term liabilities | 1,870 | 1,106 | 91 | ||
Net debt | (96,303) | (90,441) | 103,879 | ||
| Cash flow | |||||
Cash from operating activities | (47,499) | (53,845) | (25,074) | ||
CAPEX | (230) | (48) | (3,548) | ||
Cash from investing activities | (17,557) | (54,211) | (3,548) | ||
Cash from financing activities | 54,030 | 129,672 | 1,714 | ||
FCF | (645) | (75,125) | (50,170) | ||
| Balance | |||||
Cash | 98,663 | 91,651 | 19,786 | ||
Long term investments | 50 | ||||
Excess cash | 98,663 | 91,607 | 19,790 | ||
Stockholders' equity | (287,615) | (200,813) | (111,202) | ||
Invested Capital | 364,048 | 296,252 | 136,384 | ||
ROIC | |||||
ROCE | |||||
| EV | |||||
Common stock shares outstanding | 29,900 | 32,733 | |||
Price | 17.00 51.38% | 11.23 11.19% | 10.10 4.23% | ||
Market cap | 335,773 1.56% | 330,607 4.23% | |||
EV | 245,332 | 434,486 | |||
EBITDA | 406 | (74,811) | (49,980) | ||
EV/EBITDA | |||||
Interest | 6,442 | ||||
Interest/NOPBT | |||||